India’s Competition Regulator Clears KKR’s Acquisition of Majority Stake in Healthcare Global Enterprises

India’s Competition Commission has granted approval for global investment firm KKR to acquire a controlling stake in Healthcare Global Enterprises (HCG), one of the country’s leading oncology hospital chains. The transaction involves KKR purchasing up to 54% of HCG’s equity from CVC Asia V at a price of ₹445 per share, amounting to a deal valued at approximately $400 million. Following this acquisition, KKR will become the largest shareholder in HCG and assume sole control of its operations.

 

As part of regulatory requirements, KKR will also make an open offer to acquire additional shares from public shareholders, potentially increasing its stake to between 54% and 77%. Dr. BS Ajaikumar, founder of HCG, will transition to the role of Non-Executive Chairman, focusing on clinical excellence, academic advancements, and research initiatives.

 

This strategic investment marks another significant entry by KKR into India’s healthcare sector, with the firm aiming to further strengthen HCG’s offerings and expand access to advanced cancer care across the country. The transaction is expected to close by the third quarter of 2025, subject to customary closing conditions and regulatory approvals.

 

Source: Express Healthcare